ADJUVANT 5 FU-IRRADIATION-5 FU FOLLOWING MASTECTOMY IN HIGH-RISK PATIENTS

被引：0
|
作者：
RAMIREZ, G
机构：
[1] UNIV WISCONSIN,DIV CLIN ONCOL,MADISON,WI 53706
[2] UNIV WISCONSIN,DIV RADIOTHERAPY,MADISON,WI 53706
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1976年 / 17卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [31] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [32] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [33] Evaluating 5FU plasma level in colorectal cancer chemotherapy patients through continuous 5FU infusion
    Sakuyama, Naoki
    Sato, Tsuyoshi
    Kishine, Kenji
    Nagayasu, Kiichi
    Nakatani, Akinori
    Kitajima, Masayuki
    ANNALS OF ONCOLOGY, 2022, 33 : S542 - S542
  • [34] A randomized phase III trial of adjuvant radio - Chemotherapy comparing irinotecan (CPT-11), 5FU and leucovorin to 5FU and leucovorin in patients with rectal cancer
    Kalofonos, Haralabos P.
    Pentheroudakis, George
    Rigatos, Sotirios
    Papakostas, Pavlos
    Tsavdaridis, Dimitrios
    Xiros, Nikolaos
    Dimopoulos, Meletios A.
    Galani, Eleni
    Pectasides, Dimitrios
    Fountzilas, George
    ANNALS OF ONCOLOGY, 2006, 17 : 116 - 116
  • [35] 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer
    Blaschke, Martina
    Cameron, Silke
    Goeschen, Colin
    Ramadori, Giuliano
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (01) : 56 - 58
  • [36] ALTERED PHARMACOKINETICS OF HIGH-DOSE 5-FLUOROURACIL (5-FU) WITH ALLOPURINOL (HPP) AND ANALYSIS OF ROUTES OF 5-FU ACTIVATION
    SCHWARTZ, PM
    HYDE, CM
    TUREK, PJ
    CADMAN, E
    HANDSCHUMACHER, RE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 222 - 222
  • [37] MFL-P chemotherapy for pretreated metastatic breast cancer patients: A regimen with triple biochemical modulation by MTX-5FU, LV-5FU and 5FU-CDDP
    Kan N.
    Honda G.
    Breast Cancer, 1999, 6 (3) : 187 - 191
  • [38] Two Pan-European trials in adjuvant colon cancer (PETACC 1&2):: The efficacy of Tomudex® compared to bolus 5-Fluorouracil/leucovorin (5-FU/LV); and high dose infusional 5-FU compared to bolus 5-FU/LV, in patients with stage III colon cancer
    Wils, J
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [39] 5-FLUOROURACIL (5-FU) PHARMACOKINETICS FOLLOWING VARIOUS ROUTES OF ADMINISTRATION
    SADEE, W
    FINN, C
    SCHWANDT, HJ
    YALE, L
    LEE, YT
    BATEMAN, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 187 - 187
  • [40] The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients
    Scartozzi, M
    Sobrero, A
    Gasparini, G
    Berardi, R
    Catalano, V
    Graziano, F
    Barni, S
    Zaniboni, A
    Beretta, GD
    Labianca, R
    Cascinu, S
    ONCOLOGY, 2005, 68 (2-3) : 212 - 216
12345